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Abstract
The general anesthetic 2,6-diisopropylphenol (propofol) is very poorly sol-
uble in water and is normally administered in the form of an emulsion. We
demonstrated that several commercially available nonionic surfactants (Tween
80, Cremophor EL, Poloxamer 188, Poloxamer 407, Solutol HS15, and Vita-
min E TPGS) render propofol soluble with a specific solubilization capacity of
at least 0.1 g/g. The room-temperature stability of the solutions appeared to be
limited only by the chemical stability of the compounds involved. The associa-
tion between propofol and the surfactants was investigated by various NMR ap-
proaches, including measurements of diffusion coefficients,  H longitudinal re-
laxation times, and the magnitude of intermolecular nuclear Overhauser effects.
The results were consistent with the micellar solubilization mechanism of propo-
fol by the surfactants (unimer solubilization in the case of Poloxamer 188).  H
longitudinal relaxation and diffusion behavior of propofol were monoexponen-
tial in each case. Solubilization caused a considerable shortening of propofol’s
proton  
 
’s. The values of the diffusion coefficient of propofol were several per-
cent higher than those of surfactants. This was explained by the partitioning of
propofol between swollen micelles and the aqueous solution. Diffusion measure-
ments also revealed the presence of a rapidly-diffusing ethylene oxide population
in surfactant solutions, which is consistent with free poly(ethylene oxide) (PEO)
known to be present in commercially produced surfactants. The free PEO blocks
exhibited molecular association with the extramicellar propofol.
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1 Introduction
Propofol (2,6-diisopropylphenol) is a commonly used general anesthetic. In clinical
practice it is administered intravenously. It is dispensed as an isotonic oil-in-water
emulsion at a concentration of 1% (w/v) that is formulated with glycerol, soya oil,
sodium hydroxide, egg lecithin, and disodium EDTA and has a pH of 6 to 8.5.1,2
The goal of this work was to investigate the association between propofol and six
nonionic polymeric surfactants: Poloxamer 407 (F127); Poloxamer 188 (F68); Tween
80; Solutol HS15; Cremophor EL; and Vitamin E TPGS. The principal components
of Poloxamers are triblock copolymers of the general form EO
  
PO

EO
 
, where
EO = ethylene oxide and PO = propylene oxide. The average composition {n1, m,
n2} is {97, 69, 97} to {100, 65, 100} for F127 and {76, 29, 76} for F68; their aver-
age molecular weights are 12600 and 8400, respectively.3–7 Cremophor EL (average
MW 2500) is polyethoxylated castor oil, a complex mixture of surfactants with the
main component being poly(ethylene glycol)(35) glycerol triricinoleate.8 The princi-
pal components of the other surfactants are: Solutol HS15, poly(ethylene glycol)(15)
12-hydroxystearate (MW 960); Vitamin E TPGS, -tocopheryl poly(ethylene gly-
col)(22) succinate (MW 1500); Tween 80 (Crillet 4 HP, Polysorbate 80), tris-poly-
(ethylene glycol)(20) sorbitan monooleate (MW  1300).9,10 The principal criterion for
the choice of surfactants for this study was their biocompatibility and pharmacologi-
cal properties, briefly discussed below in this Section. All of the surfactants contain
free poly(ethylene oxide) (PEO) which is often added purposefully to facilitate the
industrial handling of the compounds.
Of the above list, Poloxamers are probably the most studied and the best understood,
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and have been extensively reviewed in the literature.6 Poloxamers 407 and 188 are
also available under the names Lutrol F127 (Pluronic F127) and Lutrol F68 (Pluronic
F68), respectively. Lutrol is the clinical grade of Poloxamers, extensively used in
the pharmaceutical industry. The PEO and the PPO blocks are usually thought of as
hydrophilic and hydrophobic, respectively.11 Poloxamers are thus amphiphilic block
copolymer surfactants with relatively low polydispersity. Variation of the length of
each of the blocks enables the modulation of the copolymer properties (such as micel-
lization) in a wide range of their respective values.
In this work, several NMR techniques were applied to investigate the degree and the
nature of association between the studied surfactants and propofol. The principal
findings were the following. (1) Each of the six surfactants solubilized propofol to at
least 1% (w/v) at the 10% (w/v) surfactant concentration. (2) In surfactant solutions,
poly(ethylene oxide) exhibited two diffusion coefficients, “fast” (free PEO blocks)
and “slow” (micellar PEO blocks bound to the hydrophobic tails). (3) Propofol exhib-
ited a single diffusion coefficient in all cases; its value was consistent with propofol
largely being associated with the surfactant molecules or micelles and partly residing
in the extramicellar solution. (4) In each system, the proton relaxation times of the
solubilized propofol were considerably shorter than those in a CDCl

solution or in
bulk propofol. (5) Although diffusion coefficient measurements are required to fully
understand the molecular association in the studied systems,  
 
measurements were
used to provide “quick evidence” of molecular association between propofol and the
surfactants.
The motivation for this work was, in part, the investigation of alternative delivery vehi-
cles for the intravenous administration of propofol. While the commercially available
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emulsion (Diprivan ) provides for an efficient delivery of propofol, it also has disad-
vantages. Two of these are the presence of residual free propofol in the “water” phase
which is believed to lead to pain on intravenous injection,12 and the propensity of the
emulsion to support bacterial growth.13 In recent years extensive research has been
undertaken to develop novel and robust drug delivery vehicles providing for fewer
clinical side effects.14–18 A number of nonionic surfactants appear promising in this
regard.19–21 Although problems with clinical applications of some surfactants (most
notably with Cremophor) have been pointed out,22–24 many are widely used in drug
formulations. They are generally acknowledged to have low toxicity and are well
tolerated clinically.25,26 Several compounds containing poly(ethylene oxide) (PEO)
moieties have been shown to modulate or reverse multidrug resistance in animal and
human cancer cells, with Solutol HS15 and Tween 80 being among the least toxic.27–29
Solutol HS15 has been shown to interact with plasma lipoproteins,30 and Poloxamers
with brain microvessel endothelial cells.31 Poloxamers have been shown to enhance
the delivery of drugs and ATP to cells31,32 as well as to affect the distribution of the
delivered drug inside the target cell.33 Targeted drug delivery mediated by Poloxam-
ers conjugated with an antibody has been attempted.32 Poly(ethylene glycol) coating
has been found to increase the bloodstream circulation lifetime of liposomes.34 All
of these features make PEO-containing polymer surfactants particularly interesting as
potential components of intravenous drug delivery vehicles.
The range of surfactants studied in this work was not meant to be comprehensive, with
Triton and Brij series being two of the notable omissions. However, the methodology
presented here is independent of the specific surfactant. The development of a detailed
practical example of the application of NMR to a pharmacologically relevant micellar
system formed the second part of our motivation. The NMR results described here
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are relatively easy to interpret, and the experiments used could provide a basis for a
methodology used for the in vitro evaluation of novel drug delivery systems.
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2 Experimental
Materials: Surfactants were obtained from the following sources: Tween 80 (Crillet
4 HP, CAS 9005-65-6), from Croda Chemicals (Australia); Cremophor EL (61791-
12-6), Poloxamer 188 (106392-12-5), Poloxamer 407 (106392-12-5), Solutol HS15
(61909-81-7), from BASF (Ludwigshafen, Germany); Vitamin E TPGS (9002-96-4),
from Eastman Chemicals (Kingsport, TN). The certificates of analysis of the batches
used showed that they typically consist of approximately equal amounts of the prin-
cipal amphiphilic compound and free poly(ethylene glycol), with small ( 5%) quan-
tities of impurities. Propofol (CAS 2078-54-8) was obtained from Archimica SpA
(Varese, Italy). CDCl

was purchased from Aldrich (Milwaukee, WI); CCl

(used
for magnetic susceptibility matching, spectroscopic grade), from AJAX Chemicals
(Auburn, NSW, Australia); D

O, from ANSTO (Lucas Heights, NSW, Australia). All
chemicals were used as received. Water was obtained from a Milli-Q reverse-osmosis
apparatus (Millipore, Bedford, MA).
Surfactant solutions: Typical surfactant concentration in the studied systems was
10% (w/v). The solutions were prepared by repeated vortexing and incubation at 35
ÆC to 40 ÆC over at least 24 h. Propofol was loaded into the D

O/surfactant systems
using the same cycle. For the solutions of Poloxamers, the preparation procedure
included centrifugation at 380 g to facilitate the dissolution of the surfactant. Cloud
point and gelation temperatures were estimated visually following the equilibration of
samples in a water bath.
NMR spectrometer: A Bruker (Karlsruhe, Germany) DRX-400 spectrometer with
an Oxford Instruments (Oxford, UK) 9.4 T wide-bore magnet equipped with a 1000
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G cm   z-only actively shielded diffusion gradient probe was used in the experiments.
The general setup of the spectrometer has been described elsewhere.35–39 The length
of the linear-gradient region was 1 cm in the z direction. The probe was equipped with
a number of inserts, of which the 10-mm  H-only and the 5-mm inner- P, outer- H
inserts were used for the  H diffusion measurements.  H 90Æ-pulse durations were
  20 s and 40 s, respectively. NOESY, most of the inversion recovery measure-
ments, and reference 1D measurements were performed using a 5-mm Bruker TXI
probe (typical  H 90Æ-pulse length, 8 s). Sample temperature was controlled, where
applicable, by air flow at 400 L h  . Temperature was calibrated separately for each
probe using a capillary containing methanol (low-T) or ethylene glycol (high-T).40,41
NMR samples: To ensure that the sample in diffusion measurements was completely
contained within the probe’s constant-gradient region, it was constrained to the length
of 8–9 mm. One of the following three setups was used when measuring the diffu-
sion coefficients: (1) 10-mm  H-only insert, the sample (  0.7 mL) was placed into
a cylindrical Wilmad microcell, bubbles were removed by light tapping, and the mi-
crocell was placed inside a 10-mm o.d. NMR tube containing 2.5 mL of CCl

for
magnetic susceptibility matching;37,39 (2) 10-mm  H-only insert, the sample ( 0.7 mL)
was placed into a 9-mm o.d. flat-bottom NMR tube, a 13-mm long Teflon suscepti-
bility plug was placed above the sample, and the tube was inserted into a 10-mm o.d.
NMR tube containing 1.5 mL of CCl

for magnetic susceptibility matching; (3) 5-
mm inner- P, outer- H insert, the sample was placed into a 5-mm o.d. Shigemi tube
(BMS-005B, susceptibility-matched for D

O), the sample’s length was restricted by
the susceptibility-matching rod. The typical shimming linewidth was 8–10 Hz in se-
tups (1) and (2) and 3–5 Hz in (3). When the TXI probe was used, either the standard
Wilmad 528-PP NMR tubes or the susceptibility-matched Shigemi tubes were used;
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the residual linewidth was   3 Hz in both cases. NMR spectra, diffusion coefficients,
and longitudinal relaxation times were measured at 23 ÆC. No chemical shift standard
was added, to obviate the possibility of it interacting with the micelles. Chemical shift
referencing was done on the HDO peak (set to 4.8 ppm). A small amount of CDCl

(  15% v/v) was added to bulk propofol samples for the lock signal.
NMR Measurements: A convection-compensating PGSE pulse sequence42 was used
for most diffusion measurements. Some of the room-temperature measurements were
carried out using the non-compensated PGSE sequence. Typically, 32 linearly incre-
mented values of  were used in a diffusion measurement. Trapezoidal gradient pulses
were used (ramped in 10 steps, ramp duration 0.1 or 0.5 ms; the exact value had no
identifieable effect on the quality of the measured data). The absence of convection
effects was established by comparing the results of measurements carried out with
different values of the diffusion time (e.g. 8 ms and 20 ms). Longitudinal relaxation
times,  
 
, were measured using a standard inversion recovery pulse sequence. NOESY
spectra were acquired using either the standard43 or gradient-selected44 phase-sensitive
pulse sequence. Data processing is described in detail elsewhere.35,45 The spectra of
bulk propofol were recorded with an appropriately detuned Bruker TXI probe. The
absence of radiation damping effects was checked by using a modified inversion-
recovery pulse sequence, /2 –  – /2. In the determination of relaxation times
and diffusion coefficients of micellar propofol, particular attention was paid to base-
line correction of the spectra in order to avoid distortions of the measured intensities
of the inherently small propofol peaks. In most cases, polynomial baseline correction
(0th–2nd order) was sufficient. In some cases, cubic-spline correction was used.
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3 Results
Proton NMR spectra of all the surfactant solutions in D

O were similar in that in each
of these the largest peak was that near 3.7 ppm corresponding to the CH

groups of
poly(ethylene oxide) (PEO) and poly(isopropylene oxide) (PPO), as well as the CH
protons of PPO. This peak was inhomogeneously broadened in all samples, and its
lineshape depended on the presence of propofol in the system. Other prominent peaks,
common to all or several of the compounds, were near 0.9 ppm from CH

groups
(1.2 ppm for PPO CH

groups) and (except for the Poloxamers) near 1.3 ppm from
aliphatic CH

groups. Representative spectra of three of the surfactants are shown in
Figure 1.
Propofol solubilization: initial observations. The structure of propofol and the  H
NMR spectrum of its solution in CDCl

are shown in Figure 2.  
 
values of its protons
in the CDCl

solution ranged from 1.7 s for the methyl groups to 3.6 s for the aromatic
proton in para-position to the OH group.  
 
’s in bulk propofol were approximately
half these values.
All of the surfactant solutions solubilized propofol. At room temperature, a 10% (w/v)
solution of each surfactant was capable of solubilizing propofol to at least 1% (w/v)
concentration, which corresponded to a specific solubilization capacity of 10%. The
solutions were clear, had pale to intense yellow color, and showed no opalescence.
They did not appear to “age”; all of them were chemically and physically stable for
at least 2 months at room temperature and at least 1 year at 4 ÆC. The F68 solution of
propofol formed a dark-yellow precipitate at 4 ÆC; however, a brief room-temperature
vortexing restored the system and its NMR behavior to the original state. The other
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solutions remained homogeneous liquids when cooled to 4 ÆC. We estimated clouding
point or gelation temperature of each of the six systems containing 1% (w/w) propo-
fol and 10% (w/w) surfactant in D

O-saline (P/S/D

O). The results were as follows:
P/Solutol HS15/D

O-saline, cloud point  40ÆC; P/Vitamin E TPGS/D

O-saline, liq-
uid crystalline transition (gelation)  42ÆC; P/Tween 80/D

O-saline, cloud point 
40ÆC; P/Cremophor EL/D

O-saline, cloud point  50ÆC; P/either Poloxamer/D

O-
saline, gelation  50ÆC.
 H NMR peaks from hydrophobic groups shifted to low frequency in the presence
of propofol. Table 1 lists the chemical shifts of selected peaks in the 10% (w/v)
surfactant/D

O-saline and 1% (w/v) propofol/10% (w/v) surfactant/D

O-saline sys-
tems (S/D

O-saline and P/S/D

O-saline, respectively). The average propofol-induced
low-frequency shift for the “hydrophilic” PEO CH

peaks was 0.01 0.01 ppm, while
for the “hydrophobic” ones it was 0.07  0.05 ppm. In addition, propofol effected ei-
ther a change of the lineshape or a partial splitting of the PEO peak at 3.7 ppm. The
extent of the changes depended on the surfactant.
Propofol + Solutol HS15. The micellar diffusion coefficient of PEO–HS ester in a
propofol-free Solutol solution [9.15% (w/w)] was 1.9 10    m s  . As an exam-
ple of propofol solubilization, the system consisting of 1% (w/v) propofol and 10%
(w/v) Solutol HS15 in D

O-saline (P/Sol/D

O-saline) was studied in detail. Its proton
NMR spectrum is shown in Figure 3A,B. The PEO peak near 3.7 ppm experienced
a partial splitting in the presence of propofol, which is evident from a comparison of
parts B and C of Figure 3. The two peaks from aromatic protons near 7 ppm were
used as diffusion and relaxation indicators of propofol. The CH

peak at 0.87 ppm
and the slowly diffusing component of the PEO peak at 3.73 ppm were used as indi-
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cators for the surfactant micelles. Aliphatic peaks at 1.27 ppm (PEO–HS ester) and
1.19 ppm (propofol) overlapped, and only a single  
 
and  could be determined for
these peaks. The  
 
and  values determined from the non-overlapping peaks are pre-
sented in Table 2. The peak at 1.27/1.19 ppm showed monoexponential longitudinal
relaxation in all cases, and the value of  obtained from it (1.4210    m s  ) was
consistent with those listed in Table 2. The observed value of the diffusion coefficient
of propofol was (1.44  0.1)10    m s  . The diffusion coefficient of the sur-
factant (polyethoxylated 12-hydroxystearate) in the propofol-containing solution was
(1.27  0.1)10    m s  . The NOESY spectrum of the P/Sol/D

O-saline system
revealed strong negative intermolecular NOEs between the aromatic propofol peaks
and the Solutol HS15 peaks at 3.73 and 0.87 ppm.
Propofol and other surfactants. Table 3 shows propofol and surfactant diffusion
coefficients in each of the propofol/surfactant/D

O-saline systems. In each of these,
 H PFG NMR diffusion measurements showed the presence of two PEO populations,
rapidly and slowly diffusing. In addition to the “fast” PEO population, in the two
Poloxamers the polypropyleneoxide (PPO) peak near 1.18 ppm also exhibited two
separate diffusion coefficients. In each of the six systems, the Stejskal–Tanner plots of
propofol signals were linear. The effective diffusion coefficients were slightly higher
than the “slow” diffusion coefficients of the respective surfactants. The values of all
the diffusion coefficients were independent of the diffusion interval  in the range
studied. From a comparison of several measurement methods, the relative standard
deviation of the measured diffusion coefficients was estimated to be 5%.
A study of the concentration dependence of the diffusion coefficients of the surfactants
and propofol was not made. However, measurements of the Solutol HS15/D

O-saline
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system revealed that the dependence of the micellar  of Solutol on its concentration
in D

O in the range 1–5% (w/v) was significant, i.e. exceeded the standard deviation
of the measurement. This means that the values of the diffusion coefficients reported
here should be treated as concentration-specific.
Table 4 lists the  
 
values of the two aromatic protons of propofol in three of the stud-
ied systems. The standard deviation of the reported values is conservatively estimated
at 30 ms. Propofol  
 
values in the other three systems were less precise but were
consistent with the three former systems, that is, near 500 ms.
NOESY spectra were also recorded for the propofol/Tween 80/D

O-saline system at
22 ÆC and 35 ÆC. The sorbitan–propofol intermolecular NOEs were negative at 22 ÆC
and weakly positive at 35 ÆC. The PEO–propofol NOEs were weakly negative and
weakly positive, respectively.
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4 Discussion
Although the phase diagrams of surfactant systems can be very complex,46,47 in this
work we focused only on the simple disordered micellar and unimer phases which ex-
ist in dilute solutions of surfactants. All of the studied surfactants, with the exception
of Poloxamer 188, have critical micellization concentrations well below 1% (w/v) at
biologically relevant temperatures. F68, on the other hand, exists in a 10% (w/v) water
solution in the unimer form up to 33 ÆC.7 The range of surfactants investigated thus
permitted a comparison of the micellar and the unimer solubilization of propofol.
As can be expected of high-molecular weight compounds, the room-temperature val-
ues of the diffusion coefficients of each of the surfactants in their water solutions were
of the order of 10    m s   or smaller. The proton longitudinal relaxation times
of Solutol HS15 were measured both above and below cmc. The latter values were
slightly longer than the former. This is consistent with results reported for surfactants
of similar MW,48 and with the assumption that the rotational reorientation time of a
single surfactant molecule lies near the crossover from the extreme-narrowing limit to
slow-motion limit. The proton  
 
’s in each surfactant did not exceed 1 s either above
or below cmc, and were in the range 350–700 ms when the surfactants were in mi-
cellar form. Literature values of the cmc for each of the studied surfactants are listed
in Table 5. Except for Poloxamer 188 (F68), all of the compounds are known to be
in the micellar form in water solution in the temperature range 20–40 ÆC and concen-
tration range 1–15% (w/v).5,49,50 The presence of electrolytes is known to affect the
phase diagrams of surfactant/water systems.47 However, the effect is not significant at
the physiological saline concentration (0.9% = 154 mM NaCl). This was confirmed
by our measurements carried out on pure-D

O solutions; the results were essentially
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the same as those for the D

O-saline solutions discussed below. Each surfactant con-
tains a significant quantity of free PEO whose protons have the same chemical shift
as those of the micellar surfactant PEO. Therefore, in diffusion experiments the single
PEO  H NMR peak corresponded to two non-exchanging populations, micellized and
free PEO, and exhibited two diffusion coefficients.
Propofol solubilization: initial observations. In contrast to the macromolecular
surfactants, propofol is a small molecule. It is a dark-yellow liquid almost insoluble
in water ( 150 mg/L) but soluble in many organic solvents.2,51 A comparison of the
spectrum in Figure 2 with those of the surfactants (cf. Figure 1) revealed that the two
aromatic proton multiplets near 7 ppm were always well-separated from all surfactant
peaks, and were therefore suitable as indicators of propofol behavior in surfactant
solutions. The other peaks overlapped with surfactant peaks either partially or fully.
Hence,  and  
 
values measured from the latter were generally less reliable than
those measured from the former.
The first indicators that the solubilization involved direct molecular association be-
tween propofol and the surfactants were the systematic low-frequency shift of  H
NMR signals from hydrophobic protons (Table 1) and the changes of the PEO line-
shape induced by propofol. The average low-frequency shift in the presence of 1%
(w/v) propofol for the “hydrophilic” and “hydrophobic” peaks was 0.01  0.01 ppm
and 0.07  0.05 ppm, respectively. Although the possibility of a comparison of abso-
lute shifts of such magnitude, when the referencing is done on the temperature- and
pH-dependent HDO peak, is questionable, the relative shift of one group of protons
versus the other is unambiguous. The hydrophobic non-EO CH

and CH

protons
were thus shifted to low frequency considerably more than the relatively hydrophilic
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EO CH

protons were. This is consistent with the former being in contact with do-
mains possessing a more positive magnetic susceptibility than that of D

O, which is
expected of an aromatic compound like propofol.52
Propofol + Solutol HS15. Diffusion studies of Solutol HS15 revealed that the ethy-
lene oxide peak near 3.7 ppm exhibited two diffusion coefficients which differed
roughly by about an order of magnitude and had population ratios of approximately
2(fast):1(slow). The two observed diffusion coefficients were attributed to the free
PEO and the PEO blocks of the micellized surfactant, polyethoxylated 12-hydroxy-
stearate. The diffusion coefficient of PEO–HS ester measured from the signal at 0.85
ppm was consistent with the “slow” PEO  to within 3% (see Table 2).
 
 
values of propofol indicate the local viscosity of propofol domains. In bulk-like
propofol droplets, propofol protons would have  
 
values of approximately 1 s. Propo-
fol molecules dispersed in a micellar core would experience a greater local viscosity
and therefore have longer reorientation times and shorter  
 
values.  
 
values of
propofol protons thus allow us to distinguish between bulk-like propofol and propofol
dispersed in the micellar core. (This can be compared to the hydration test in W/O
microemulsions which has been used to distinguish between bulk-like “active” water
and water dissolved in oil.53) In the system propofol/Solutol HS15/D

O-saline, the  
 
values of propofol protons are considerably shorter than in bulk propofol, indicating
that propofol domains inside the micelles do not possess a bulk-like viscosity. On the
other hand, a partial splitting of the PEO peak was present in this system (cf. Figure
3B,C). The diffusion coefficient of propofol-loaded PEO–HS micelles was smaller
than the micellar  in the system Solutol HS15/D

O-saline (1.9 10    m s  ) by a
factor of 1.5. This proves that the uptake of propofol increased the size of the surfac-
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tant micelles. The observed specific solubilization capacity of  10% is plausible for
micellar solubilization.54,55
The observed diffusion coefficient of propofol was close to, but slightly higher than,
the observed micellar diffusion coefficient of PEO–HS ester (1.9 10    m s  ). For
a single system, this could be attributed to an experimental error. However, the results
for other surfactants, presented in Table 3, revealed that this was a consistent phe-
nomenon. We surmise that the explanation lies in the partitioning and fast chemical
exchange of propofol molecules between the micelles and the extramicellar medium.
The solubility of propofol in water (  150 mg/L) is sufficiently high to account for
the difference between the two diffusion coefficients. However, the presence of inter-
molecular NOEs between PEO and propofol indicates that the extramicellar propofol
is likely to be associated with the free PEO blocks. This model is illustrated in Figure
4. The observed propofol diffusion coefficient is thus the weighted average of the dif-
fusion coefficients of micelles and the free PEO.45 The respective values correspond
to approximately 1% of propofol residing in the latter. This outcome is plausible
considering that PEO blocks constitute the relatively hydrophylic head of the Solutol
molecule, while the 12-hydroxystearic acid moiety forms the hydrophobic tail.
Propofol and other surfactants. Free PEO was present in all of the studied surfactant
solutions. There was a loose correlation between its diffusion coefficient and the size
of the PEO block in the surfactant molecule. The diffusion coefficient of HDO was
in the range (1.1–1.5)10  m s   for all samples, meaning that the values of the
effective hydrodynamic viscosities of the solutions were within 40% of each other. In
the Poloxamer solutions, the two diffusion coefficients measured from the PPO peak
near 1.18 ppm were interpreted as belonging to the free PPO and the micellar PPO
18
populations, respectively.
With the exception of the Poloxamers, the observed diffusion coefficients of propofol
(Table 3) were very close to but a few per cent higher than the values of the micel-
lar diffusion coefficients of the respective surfactants. The explanation is the same as
in the case of Solutol HS15. Propofol molecules essentially resided in the micelles.
However,  1% of the total propofol was associated with free PEO. The latter pos-
sessed a relatively large  value, which caused the observed diffusion coefficient of
propofol to be slightly larger than that of the micelles.
In the case of the Poloxamers, the more hydrophobic free PPO was also present in the
solution. This further increased the apparent diffusion coefficient of propofol. The
large difference between the apparent  of propofol and the micellar  of the sur-
factant can be misleading. Assuming that half of all PO is in the free-PPO form and
that the affinity of propofol to free PPO is much greater than to the free PEO,  15%
of propofol needs to be associated with the free PPO in order to explain the apparent
propofol  values in the two Poloxamer solutions. This would correspond to an ex-
tramicellar concentration of propofol of 0.15% (w/v), which significantly exceeds its
solubility in water, 0.015% (w/w).9 This supports the hypothesis that the extramicellar
propofol is associated with PEO or PPO blocks rather than present in the free form.
Poloxamer 188 is a special case because it does not micellize under the conditions
used in the present study. This was reflected in its “slow”  being almost an order
of magnitude greater than that of F127, although the lengths of the unimers differ
by only a factor of 1.4–1.5. This implies that micelles were indeed absent from the
Poloxamer188/propofol/D

O-saline system, and the “slow”  was that of the unimer.
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The value of the observed diffusion coefficient of propofol in this system was consis-
tent with the foregoing model; the measured values of the unimer diffusion coefficient;
and with the assumption that the majority of propofol molecules are associated with
the Poloxamer188 unimers. Therefore, Poloxamer188 solubilized propofol despite
not being able to form micelles under the investigated conditions. At the same time,
the copolymeric unimer is a “mini-micelle” in its own right, because it possesses a
hydrophobic (PPO) and two hydrophilic (PEO) blocks. These blocks act as a core and
a corona of the “mini-micelle”, respectively.
Micellar size and hard-sphere reorientation time can be formally estimated from the
micellar diffusion coefficients using the Stokes-Einstein model as 	  
 ,


 
  , where 
 is Boltzmann’s constant,   is the temperature; , solvent vis-
cosity; 

, molecular reorientation time; and 	 and  are molecular hydrodynamic
radius and volume, respectively. These estimates, assuming that the viscosity of the
solution is that of D

O, 1.157cP, are given in Table 6. However, they are not in-
dicative of actual molecular reorientation times, as will be evident from the following
discussion. Because there is no direct relationship between the micellar hydrodynamic
radius and aggregation number,6 the values in Table 6 should not be used to estimate
the latter.
Consistent with the micellar solubilization of propofol is the shortening of its pro-
ton  
 
values in surfactant solutions. It is clear that its uptake by surfactant micelles
caused a lengthening of the molecular reorientation time of propofol; however, it was
problematic to estimate by how much, based on the available experimental informa-
tion. The reorientation time of propofol in CDCl

was estimated from propofol’s
molecular size and solvent viscosity at  0.03 ns. Using the well-known expression
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for the contribution to 1/ 
 
from dipolar relaxation by like spins, we could verify
that no value of rotational correlation time 

produced a  
 
shortening from 3.5 s
in CDCl

to   600 ms (see Table 4). Therefore, proton relaxation in propofol must
have had contributions from mechanisms other than intramolecular dipolar interac-
tion, which precluded a simple estimate of 

. At the same time, it is clear that the
hard-sphere micellar reorientation times from Table 6 are several orders of magnitude
greater than realistic values of the rotational correlation times of either propofol or the
surfactants. Therefore, the only conclusions that we can draw are: (1) that molecu-
lar reorientation of propofol and the surfactants within the micelles is determined by
intra-micellar degrees of freedom rather than by rigid-sphere micelle reorientation;
and (2) that proton relaxation in propofol in the surfactant solutions is more complex
than a single-mechanism intramolecular homonuclear dipolar relaxation.
As discussed above, the room-temperature intermolecular NOEs between Solutol HS15
and propofol were prominently negative. For the system propofol/Tween 80/D

O-
saline, they were negative at 22 ÆC and weakly positive at 35 ÆC. The crossover point
from the positive to the negative NOE corresponds to the molecular reorientation time
of 

=

/2, that is, 0.44 ns for proton–proton NOEs at 400MHz. Again, it
is clear that propofol and surfactant molecules undergo a facile mutual reorientation
within the swollen micelles, as its timescale is several order of magnitude smaller than
the hard-sphere reorientation time values shown in Table 6. The temperature trend in
the system P/T80/D

O-saline is therefore consistent with the shortening of molecular
reorientation times as the temperature is increased.
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5 Conclusions
In this work we aimed to characterize various physical-chemical factors associated
with propofol–surfactant systems. The main conclusions were: (1) Neither the chem-
ical shift nor the  
 
of free PEO blocks are resolved from those of the micellar
PEO forming the hydrophilic heads of respective surfactants. However, the free PEO
manifests itself in diffusion experiments as a fast-diffusing component of the methy-
lene  H NMR peak (3.7 ppm). (2) Micellar diffusion coefficients (or, in the case of
non-micellar Poloxamer 188, the unimer) were approximately an order of magnitude
smaller than those of the fast-diffusing PEO or PPO. (3) The two values were well-
resolved in Stejskal–Tanner diffusion plots. (4) Each of the six surfactants solubilizes
propofol with the specific solubilization capacity of at least a 0.1 g/g in the surfactant
concentration range 0–10% (w/v). (5) In solutions of Solutol HS15, Cremophor EL,
Tween 80, and Vitamin E TPGS, approximately 1% of the total propofol was parti-
tioned into the free PEO, with the rest residing in surfactant micelles. (6) In solutions
of the two Poloxamers, approximately 15% of total propofol was associated with the
free PPO, with the rest associated with Poloxamer. (7) In each case, propofol ex-
hibited a single -independent diffusion coefficient which was the weighted average
of the two populations, which suggests the presence of fast chemical exchange be-
tween them. (8) The stability of solutions at both room temperature and 4ÆC and high
( Æ) clouding point and gelation temperatures suggest the possibility of their use
in pharmaceutical formulations.
The practical aim of the study was to investigate novel micellar formulations of propo-
fol potentially appropriate for intravenous administration. Many clinically relevant
issues were outside the scope of the present study. These include, among others, sus-
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ceptibility to bacterial growth; interaction with plasma proteins; hemo- and hepatotox-
icity; interaction with cell membranes; pain on injection; and interaction with those
metabolites which can be present in the body in high concentrations (such as urea56).
Some nonionic surfactants (such as Triton or Brij) were also outside the scope of this
work, but would probably be good candidates of a future study.
However, at least two clinically relevant issues are noted on the basis of the results pre-
sented here. The first is the issue of micellar versus unimer solubilization of the drug.
It appears that the surfactant’s facility for unimer solubilization of propofol could be
a prerequisite for its intravenous use under some conditions, namely, when the uptake
of the drug is slow and the injection results in a dilution of the surfactant to a concen-
tration below its cmc. At least one surfactant, Poloxamer 188, is capable of unimer
solubilization of propofol. Significant solubility enhancements of hydrophobic com-
pounds have been noted for other Poloxamers at concentrations below their respective
cmc values.11 However, the unimer solubilization capacity of the other surfactants is
unclear and requires further investigation.
The second issue is that of the pain experienced by patients on intravenous adminis-
tration of propofol. With Diprivan emulsion, the pain has been attributed to the free
propofol present in blood due to its non-zero solubility in aqueous media. In this
respect, the partitioning of propofol into the free ethylene oxide is a negative factor,
because free PEO-associated propofol is likely to contribute to the pain experienced
by patients. We suggest that the use of purified surfactants, from which the free PEO
has been removed chromatographically or otherwise, could provide for a smaller con-
centration of extramicellar propofol. This will be the subject of further study.
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FIGURE CAPTIONS
Figure 1. Proton NMR spectra of: (A) Tween 80; (B) Vitamin E TPGS; (C) Polox-
amer 407 (all at 10% (w/v) concentration in D

O-saline). In (A) and (B), the biggest
peak (3.7 ppm) is a superposition of –CH

– peaks from the micellized and the free
PEO blocks. In (C), it is a superposition of the same peaks from the same two PEO
populations as well as –CH– peaks both from the micellar and the free PPO blocks.
The peak near 0.9 ppm in (A) and (B) is from aliphatic CH

groups. The peak near
1.3 ppm in (A) belongs to aliphatic (non-EO) –CH

– groups. The peak near 1.1 ppm
in (C) is from PPO CH

groups. The smaller peaks in the aliphatic region in (A) and
(B) belong to various moieties of the hydrophobic sorbitan and Vitamin E tails, re-
spectively.
Figure 2. Chemical structure of propofol and its  H NMR spectrum in a CDCl

solu-
tion. Assignments (400 MHz, Æ): 7.15 (d, J = 7.6 Hz, 2H, Ar H

and H

), 7.00 (t, J =
7.6 Hz, 1H, Ar H

), 4.89 (br s, 1H, OH), 3.25 (septet, J = 6.9 Hz, 2H, –CH(CH

)

),
1.36 (d, J = 6.9 Hz, 12H, CH

),
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Figure 3. (A) Proton NMR spectrum of the system 1% (w/v) propofol/10% (w/v) So-
lutol HS15/D

O-saline (P/Sol/D

O-saline). This spectrum is representative of other
P/surfactant/D

O-saline systems studied. The solids arrows (peaks a, b) show propofol
peaks which were used for the determination of its diffusion coefficient. The dashed
arrows (peaks c, d) show other propofol peaks. Peak e belongs to PEO–HS ester; it
was not used because of the overlap with the propofol peak.
(B, C) Detail of the PEO lineshape in propofol/Solutol HS15/D

O-saline and Solutol
HS15/D

O-saline, respectively. Propofol induced a partial splitting of the PEO peak.
Figure 4. Reaction scheme depicting the association of propofol with surfactant mi-
celles and free PEO blocks in surfactant solutions. Based on the values of the ob-
served diffusion coefficients shown in Table 3, approximately 99% of propofol in
non-Poloxamer solutions is micellized. In Poloxamer solutions, PEO is replaced by
PPO and the fraction of micellized propofol was estimated to be approximately 85%.
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TABLES
Table 1: Chemical shifts (ppm) of several  H NMR peaks of propofol-free and
propofol-containing surfactant solutions in D

O-saline. The HDO peak was used as a
reference (set nominally to 4.8 ppm).
10% (w/v) S/D

O-saline 1% (w/v) P/10% (w/v) S/D

O-saline
Surfactant PEO/PPO
CH


non-EO
CH


PPO or
non-PPO
CH


PEO/PPO
CH


non-EO
CH


PPO or
non-PPO
CH


F68 3.722 – 1.188 3.720 – 1.169 and
0.994
F127 3.724 – 1.170 3.710 – 1.050
Sol15 3.721 1.325 0.928 3.728 1.273 0.868
T80 3.720 1.323 0.915 3.708 1.256 0.857
CEL 3.722 1.321 0.920 3.707 1.250 0.851
VE 3.712 1.280 0.881 3.689 1.270 0.853

“hydrophilic”

“hydrophobic”
 PPO
 aliphatic non-PPO
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Table 2:  H NMR longitudinal relaxation times and  H-determined diffusion coef-
ficients in the system 1% (w/v) propofol/10% (w/v) Solutol HS15/D

O-saline. The
standard deviation of the reported  
 
values was 30 ms; that of the diffusion coeffi-
cient values was 0.0710    m s  .
Æ (ppm) Compound  
 
(ms)  (m s  )
6.93 P 570 1.4210   
6.74 P 570 1.4710   
3.73 Sol15 590 1.2510    (28%)
1.3910   (72%)
0.87 Sol15 560 1.2910   
 12-hydroxystearate-bound micellar PEO
 free PEO
Table 3: Values of the apparent diffusion coefficients of propofol and surfactants in the
respective 1% (w/v) propofol/10% (w/v) surfactant/D

O-saline systems. The relative
standard deviation of the diffusion coefficient values was  5%.
 (m s  )
Surfactant Propofol Surfactant (slow
component)
Fast PEO compo-
nent
Fast PPO compo-
nent
Sol15 1.4410    1.2710    1.3910   n/a
T80 1.6410    1.4210    3.7210    n/a
CEL 1.4710    1.4010    1.0610   n/a
VE 1.2010    1.0410    3.5910    n/a
F68 7.1010   5.4310   2.0310    1.6210   
F127 2.6510   6.8510   2.0510    1.5510   
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Table 4: Longitudinal relaxation time ( 
 
) of aromatic protons in solubilized propofol.
The typical standard deviation of the  
 
values was 30 ms.
 
 
(ms)
Surfactant H

, H

H

Sol15 570 570
F68 630 710
F127 560 610
Table 5: Literature values of the critical micellization concentration of the studied
surfactants.
Surfactant cmc (% w/v) cmc (mM) T (ÆC) Reference
F68 15 17.9 27 7
7 8.333 40
F127 4 3.174 20 7
0.7 0.555 25
0.008 0.006 40
Sol15 0.02 0.21 25 57
T80 0.0013 0.01 25 58
CEL 0.01 0.04 25 8
VE 0.02 0.13 37 50
Abbreviations: F68, Poloxamer 188 (Lutrol F68); F127, Poloxamer 407 (Lutrol
F127); Sol15, Solutol HS15; T80, Tween80 (Crillet 4 HP, Polysorbate80); CEL, Cre-
mophor EL; VE, Vitamin E TPGS.
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Table 6: Estimated micellar diameter and rigid-sphere micellar reorientation time for
the studied surfactants. Rigid-sphere reorientation times greatly exceeded realistic
values of molecular correlation times of both the surfactant and propofol (refer to
Discussion). The nominal error intervals were calculated assuming that the relative
standard deviation of the  values was 5%.
Surfactant d (nm) 

(ms)
Sol15 15  0.8 3.8  0.5
T80 13  0.7 2.7  0.4
CEL 13  0.7 2.8  0.5
VE 18  0.9 6.9  1.0
F68 35  1.8 49  7
F127 274  14 24000  3500
 Obtained using the Stokes–Einstein model (see text). The viscosity of the solution
taken as (D

O) = 1.157 cP,59 T = 23 ÆC.
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